PTRS - probability of technical and regulatory success - is an estimate of the likelihood that an asset clears the remaining technical and regulatory hurdles to reach approval. It is the single number that most directly shapes risk-adjusted value and go/no-go calls at each phase gate.
Why one number is never enough
PTRS answers “can it succeed technically and pass regulatory review?” - but a molecule can be technically sound and still be a poor portfolio decision. That is why PortiVix separates PTRS from other risk lenses:
- Business risk - commercial viability, competition intensity, and strategic fit.
- IP risk - freedom-to-operate, patent vulnerability, and patent-cliff exposure.
- API / supply risk - supplier concentration, lead time, country risk, and regulatory supply exposure.
- KSM risk - tenant-defined key success metrics with scoring and commentary.
PTRS at the phase gate
At a gate, PTRS feeds directly into eNPV: the risk-adjusted value of an asset scales with its probability of success. A high-revenue molecule with weak PTRS can be worth less to the pipeline than a modest asset with a strong probability of success. Reviewing PTRS, the other risk scores, and eNPV together - with commentary and go/kill evidence attached - is what makes a phase-gate decision defensible.
From score to decision record
The value of PTRS is not the estimate itself but the decision it supports. When PTRS, business, IP, API/supply, and KSM scores sit next to NPV/eNPV and a project risk register on the same molecule record, a gate review becomes a decision you can stand behind - and reconstruct - later.